Good evening :)
$
₹
Avita Medical Ltd

Avita Medical Ltd

RCEL

NASDAQ
Asset Logo

Avita Medical Ltd

RCEL

NASDAQ
$16.061.56% (-0.25)
$
₹
$16.061.56% (-0.25)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $474.1M the stock is ranked 3316

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

11.76
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.42
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-56.96%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

-17.44%

Earnings Growth

+116.96%

Rev. Growth

+75.28%

See Detailed Forecast

Company Profile

Company Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -17.44% growth, versus a trailing 3-year CAGR of 16.09%.

2026
Current$16.32Baseline
Analyst Target - 1 year
Target$13.47-17.44%

All values in $

202220232024202520262027$6.82$10.53$14.24Target-17.44%
2026
Current$16.32Baseline
Analyst Target - 1 year
Target$13.47-17.44%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 75.28% growth, versus a trailing 3-year CAGR of 27.66%.

2025
Current$71.61Baseline
Forecast for Dec 2026
High$126.58+76.78%
Average$125.51+75.28%
Low$124.55+73.93%

All values in $ Million

2022202320242025202634.4250.1464.2571.61Low+73.93%Average+75.28%High+76.78%
2025
Current$71.61Baseline
Forecast for Dec 2026
High$126.58+76.78%
Average$125.51+75.28%
Low$124.55+73.93%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.46Baseline
Forecast for Dec 2026
High$1.48+160.09%
Average$0.42+116.96%
Low$-1.34+45.65%

All values in $

20222023202420252026-1.54-2.14-3.33-2.46Low+45.65%Average+116.96%High+160.09%
2025
Current$-2.46Baseline
Forecast for Dec 2026
High$1.48+160.09%
Average$0.42+116.96%
Low$-1.34+45.65%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

17
-13.1
17.6
-11.6
19.2
-10.6
21.7
-7.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue11.1015.1919.5418.4018.5118.4117.0617.6119.2521.70
Net Income-18.65-15.39-16.20-11.58-13.85-9.92-13.18-11.62-10.61-7.66
Net Profit Margin-168.02%-101.30%-82.90%-62.96%-74.85%-53.86%-77.28%-65.96%-55.11%-35.31%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Avita Medical Ltd -11.76-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare RCEL with any stock or ETF
Compare RCEL with any stock or ETF
Comparing from
RCEL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Avita Medical Ltd (RCEL) share price today is $16.06 as of November 5, 2026 at 8:25 PM IST. The stock touched a day high of $16.11 and a day low of $15.67.

  2. Avita Medical Ltd stock trades on NASDAQ under the ticker symbol RCEL.

  3. Avita Medical Ltd's market capitalization is $474.1M as of November 5, 2026 at 8:25 PM IST.

  4. Avita Medical Ltd's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Avita Medical Ltd's price-to-book (P/B) ratio is 11.76 as of November 5, 2026.

  6. Yes, You can buy Avita Medical Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Avita Medical Ltd shares in three steps: 1. Search Avita Medical Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Avita Medical Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Avita Medical Ltd (RCEL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6224 shares at the current price of $16.06.

Loading...